malaria

A study led by Xavier Fernández Busquets, director of the joint ISGlobal-IBEC Nanomalaria unit, describes an innovative approach to selectively eliminate red blood cells infected by Plasmodium falciparum, avoid their aggregation, and inhibit parasite growth.

The strategy, based on the use of nanovesicles coated with antibodies that target a parasite protein, and loaded with an antimalarial drug, represents a promising alternative in the treatment of severe malaria.